News & Publications
Cellipont Bioservices and Secretome Therapeutics Partner for cGMP Manufacturing for Master Cell Bank for Lead Asset STM-01
THE WOODLANDS, Texas and DALLAS, Jan. 22, 2025 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing therapies...
Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies
DALLAS--(BUSINESS WIRE)--Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the successful closing of a $20.4 million round of financing. This funding will enable Secretome to...
Secretome Therapeutics, Inc. Announces Composition of Matter Patents for Lead Assets STM-01 and STM-21
Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the allowance of a composition of matter patent for its lead asset, STM-01, a novel nCPC product. Recently, a composition of matter patent was also issued for STM-21, the company’s lead secretome product derived from nCPC.
HEST Investments Leads $1.8 Million SPV Investment in Secretome Therapeutics to Advance Human Trials
DALLAS, Sept. 17, 2024 /PRNewswire/ -- HEST Investments, a Dallas-based venture capital family office renowned for its focus on innovative and bleeding edge ventures, proudly announces its successful SPV (Special Purpose Vehicle) of a $1.8...
Secretome Therapeutics Appoints Margot Connor as Board Director and Assembles World-Class Clinical Advisory Board
DALLAS--(BUSINESS WIRE)--Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells (nMSC) today announced the appointment of Margot Connor to its Board of Directors. “Margot’s unparalleled experience in...
Secretome Therapeutics Presents Scientific Poster on the Essential Role of Complete Secretome in Regenerative Cell Therapy at ISSCR 2023 Annual Meeting
[DALLAS, TX - May 12, 2023] — Secretome Therapeutics, a pioneering biotechnology company focused on developing regenerative cell therapies, is pleased to announce its participation in the prestigious ISSCR 2023 Annual Meeting, held at the Boston Convention and...
Comparative efficacy and mechanism of action of cardiac progenitor cells after cardiac injury
Abstract Gunasekaran et al demonstrate that human neonatal Mesenchymal Stem Cells (nMSCs) evade from macrophage mediated phagocytosis via increased CD47 expression and to promote functional recovery by secretion of exosomes and independent cytokines. The increased...
Circulating exosomes derived from transplanted progenitor cells aid the functional recovery of ischemic myocardium
Abstract The stem cell field is hindered by its inability to noninvasively monitor transplanted cells within the target organ in a repeatable, time-sensitive, and condition-specific manner. We hypothesized that quantifying and characterizing transplanted cell–derived...
Stem Cell Therapy for Hypoplastic Left Heart Syndrome: Mechanism, Clinical Application, and Future Directions
Abstract Hypoplastic left heart syndrome is a type of congenital heart disease characterized by underdevelopment of the left ventricle, outflow tract, and aorta. The condition is fatal if aggressive palliative operations are not undertaken, but even after the complete...
Regenerative medicine therapy for single ventricle congenital heart disease
Abstract One of the most complex forms of congenital heart disease (CHD) involving single ventricle physiology is hypoplastic left heart syndrome (HLHS), characterized by underdevelopment of the left ventricle (LV), mitral and aortic valves, and narrowing of the...